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Cutaneous glucocorticoid receptor sensitivity
and pro-inﬂammatory cytokine levels in
antidepressant-resistant depression
PETER FITZGERALD, SINEAD M. O’BRIEN, PAUL SCULLY, KIM RIJKERS,
LUCINDA V. SCOTT AND TIMOTHY G. DINAN*
Department of Psychiatry & Alimentary Pharmabiotic Centre, University College Cork, Ireland
ABSTRACT
Background. There is evidence to indicate that peripheral glucocorticoid receptor (GR) function
is reduced in major depression, and a possible molecular explanation for this is the impact of
raised pro-inﬂammatory cytokines. The topical steroid vasoconstriction assay provides a con-
venient probe of peripheral GR function. The present study sought to assess the sensitivity of
peripheral GRs in antidepressant-resistant major depressives and investigate the association
between GR sensitivity and circulating plasma cytokines.
Method. Nineteen antidepressant-resistant depressives together with age- and sex-matched healthy
controls underwent the steroid vasoconstriction assay using three commercial preparations of
corticosteroids containing clobetasol propionate 0.05%, betamethasone valerate 0.1%, and
clobetasone butyrate 0.05%, corresponding to very potent, potent, and moderately potent steroid
creams respectively. The pro-inﬂammatory cytokines, tumour necrosis factor-alpha (TNF-a) and
interleukin-6 (IL-6) were measured using enzyme-linked immunosorbent assays. The severity of
the depressive episode was assessed using the Hamilton Depression Scale (HAMD).
Results. Depressed subjects had a signiﬁcantly reduced vasoconstriction response across all three
strengths of steroid. They also had signiﬁcantly higher concentrations of TNF-a and IL-6. There
was a signiﬁcant inverse correlation between TNF-a concentration and vasoconstriction response
and also between the HAMD score and vasoconstriction response.
Conclusions. These ﬁndings suggest that cutaneous GR function is abnormal in antidepressant-
resistant depression, that circulating TNF-amay play a signiﬁcant role in this abnormality and that
the eﬃcacy of topical steroids in antidepressant-resistant depressives is reduced.
INTRODUCTION
Hyperactivity of the hypothalamic–pituitary–
adrenal (HPA) axis in patients with major
depression is one of the most consistent
ﬁndings in biological psychiatry. Abnormalities
include increased concentrations of cortisol
in plasma, urine and cerebrospinal ﬂuid (Gold
et al. 1988), an exaggerated cortisol response to
adrenocorticotropic hormone (Nemeroﬀ, 1996),
and a lack of suppression of cortisol in the
dexamethasone suppression test (Carroll et al.
1981). It is postulated that these changes are
due to an increase in the combined eﬀects of
the releasing factors, corticotrophin-releasing
hormone and vasopressin, and a decrease in
negative feedback control (Dinan et al. 2005).
The latter may be due to a reduced sensitivity of
the glucocorticoid receptor (GR), a view that is
supported by the lack of cushingoid stigmata in
hypercortisolaemic depressed patients (Murphy,
1991) and of abnormalities in GRs in peripheral
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blood cells (Yehuda et al. 1993). This suggests
that GR dysfunction generalizes to tissues
outside the HPA axis.
Corticosteroids inﬂuence vascular tone
(Brenner et al. 1989) and cause blanching of
the skin when topically applied. This cutaneous
vasoconstrictor response has been used to
compare the potency of topical steroids, as a
high degree of blanching reﬂects high anti-
inﬂammatory potency (Barry & Woodford,
1978). Vascular smooth muscle contains both
GRs and mineralocorticoid receptors (MRs)
(Scott et al. 1987) but only the GR is involved
in cutaneous vasoconstriction (Gaillard et al.
1985).
A recent study has shown that patients
with major depressive disorder have impaired
sensitivity of peripheral GRs as demonstrated
by reduced cutaneous vasoconstriction to
topical steroids (Cotter et al. 2002). Although a
signiﬁcantly reduced response in depressives
was found, no diﬀerence was observed between
cortisol suppressors and non-suppressors.
It has been hypothesized that the altered
GR function in major depression occurs via
ligand-independent mechanisms involving
signal-transduction pathways driven by com-
pounds unrelated to steroids such as cytokines
(O’Malley et al. 1995). Studies indicate that GR
function can be inﬂuenced by pro-inﬂammatory
cytokines via inhibition of GR translocation
from cytoplasm to nucleus (Miller et al. 1999)
and inhibition of GR-mediated gene transcrip-
tion (Pariante et al. 1999). Patients with major
depression have increases in pro-inﬂammatory
cytokines such as interleukin-1 (IL-1), inter-
leukin-6 (IL-6) and tumour necrosis factor-
alpha (TNF-a) (Anisman et al. 1999; Maes,
1999). Moreover, pro-inﬂammatory cytokines
are potent inducers of a syndrome of sickness
behaviour that has many features in common
with major depression, including anhedonia,
anorexia, sleep disturbance and impaired cog-
nition (Miller et al. 1999).
Our study sought to replicate the previous
studies of altered steroid-induced vasocon-
striction (SIV) major depression in a group of
antidepressant-resistant depressives while also
measuring their pro-inﬂammatory cytokine pro-
ﬁles using high-sensitivity assays. We hypoth-
esized that reduced cutaneous blanching in
patients with depression would correlate with
increased levels of circulating pro-inﬂammatory
cytokines.
METHOD
Subjects
We recruited 38 physically healthy subjects
between the ages of 25 and 65 years with the
approval of the Ethics Committee of the Cork
Teaching Hospitals. All participants gave fully
informed written consent. The patient group
comprised 13 females and 6 males with a
mean¡S.E.M. age of 46.4¡2.92 years, all of who
met the DSM-IV diagnostic criteria for major
depression (without psychotic features). The
Hamilton Depression Scale (HAMD) was used
to measure severity of depression. All patients
had been treated for at least 6 weeks with an
adequate dose of antidepressants (see Table 1)
but failed to reduce their HAMD score by at
least 50%. Patients were age- and sex-matched
within 5 years of controls (mean¡S.E.M. age
of controls was 40.1¡2.44 years). Controls
were recruited from a pool of known healthy
volunteers.
Exclusion criteria were co-morbid psychiatric
disorders in those with depression; current/past
Table 1. Patient characteristics including ﬁnal
antidepressant dose which was sustained for
at least 6 weeks
Subject
no. Age (yr) Sex
HAMD
score Medication
Dose (mg)
daily)
1 57 F 31 Venlafaxine 225
2 44 F 35 Fluoxetine 60
3 55 F 28 Citalopram 60
4 64 F 25 Citalopram 60
5 46 F 23 Moclobemide 600
6 54 F 27 Venlafaxine 150
Mirtazepine 30
7 25 F 20 Fluoxetine 40
8 59 F 14 Citalopram 60
9 41 F 12 Fluoxetine 60
10 38 F 25 Sertraline 200
11 57 F 20 Fluoxetine 40
12 56 F 31 Venlafaxine 150
Mirtazepine 30
13 57 F 20 Paroxetine 40
14 41 M 20 Venlafaxine 225
15 63 M 13 Citalopram 40
16 22 M 10 Venlafaxine 150
17 34 M 27 Imipramine 150
18 32 M 18 Paroxetine 60
19 38 M 31 Venlafaxine 150
Reboxetine 8
HAMD, Hamilton Depression Scale.
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psychiatric illness in controls or their ﬁrst-
degree relatives and, for both groups, the
presence of inﬂammatory or allergic conditions,
recent or current use of corticosteroids and
concurrent physical illness.
Procedures
SIV assay
Three commercial preparations of cortico-
steroids containing clobetasol propionate
0.05%, betamethasone valerate 0.1%, and
clobetasone butyrate 0.05%, corresponding
to very potent, potent, and moderately potent
steroid creams (Pardasani et al. 2000) were
used to perform the vasoconstrictor assay.
These widely available steroid creams provide
a convenient probe of GR function and have
been previously used in vasoconstriction studies
(Marks et al. 1982). All steroid assays were
carried out between 15:00 and 17:00 hours. In a
single-blind random order, each of the creams
was applied in 20-ml aliquots with the total
amount suﬃcient to cover a well-circumscribed
area of 2 cm diameter to the volar surface of the
forearm of each subject. Non-reactive plastic
guards with a circular diameter of 2 cm were
used to ensure that each concentration was
applied to a standardized area.After application,
the forearm was wrapped in plastic clingﬁlm
to enhance percutaneous absorption of the
corticosteroid and protect the forearm from
contamination. Subjects were instructed to keep
the forearm free from water for the duration of
the study.
The clingﬁlm was removed between 08:00
and 09:00 hours the next morning in order
to allow resolution of any reactive hyperaemia
before inspection. All examinations were carried
out 18 hours after application of the creams
under standardized conditions. A trained ob-
server, blind to the potency of the steroid,
assessed the degree of skin blanching using a
4- point scale to yield a SIV score : 0=no
blanching; 1=faint blanching; 2=obvious
blanching extending to the boundary of appli-
cation; 3=intense blanching extending beyond
the application site.
Assays
On the morning the vasoconstriction assay
was started 6 ml of whole blood was collected
between 09:00 and 11:00 hours in ethylene-
diaminetetraacetic acid (EDTA) tubes. Samples
were centrifuged immediately and plasma frozen
at x80 xC. IL-6 and TNF-a were measured in
duplicate by enzyme-linked immunosorbent
assays (ELISA). The dynamic range of the IL-6
assay varies between 0.16 and 10.0 pg/ml with
an intra-assay coeﬃcient of variation of 8.33%
and an inter-assay coeﬃcient of variation of
10.00% at the 2.0-pg/ml level. The range of the
TNF-a assay varies between 0.5 and 32.0 pg/ml
with an intra-assay coeﬃcient of variation of
6.7% and an inter-assay coeﬃcient of variation
of 8.2% at the 6.1-pg/ml level. Samples were
also taken for measurement of plasma cortisol
using an unextracted, non-chromatographic
radioimmunoassay. The coeﬃcient of variation
at both 100 nmol/l and 1000 nmol/l was 6%.
Statistics
Parametric data (including pro-inﬂammatory
cytokines and cortisol) were compared using
two-tailed Student’s t tests. SIV scores were
compared using x2 tests. Spearman rank corre-
lations were used to test for associations be-
tween cytokine levels, HAMD scores, and SIV
scores. GraphPad Prism version 4 for Windows
(GraphPad Software, San Diego, CA, USA)
was used for statistical analysis.
RESULTS
SIV
There was a highly signiﬁcant diﬀerence in the
distribution of blanching scores between the
depressives and controls across all steroid
strengths, with depressives having decreased
SIV compared to controls (see Fig. 1). One
hundred per cent of the controls showed full
(blanching to the periphery of the test ring) or
greater blanching to all three topical steroid
creams, while this was markedly reduced in the
depressive sample. Seventy nine per cent (79%)
of depressives showed full blanching to the very
potent topical steroid; this decreased to 26.3%
in response to moderately potent steroid; and
none had full blanching to the potent topical
steroid. The comparisons were as follows:
very potent topical steroid (x2=38.0, df=3,
p<0.001); potent topical steroid (x2=23.3,
df=3, p<0.001) and moderately potent topical
steroid (x2=16.1, df=3, p<0.001).
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The depressive group was subdivided ac-
cording to HAMD scores into a mild-moderate
depression group (HAMD scores from 18 to 25)
and a severe depression group (HAMD <25),
and comparison was made between their group
status and SIV scores (see Fig. 2). None of
the mild-moderate depressives exhibited a full
skin-blanching response to application of the
moderately potent topical steroid; this increased
to 42% in response to the potent steroid, and
91% showed full skin-blanching to the very
potent topical steroid. For the severely depressed
group, however, there was a marked reduction
in skin-blanching response with none exhibiting
a full vasoconstriction response to either the
moderately potent or potent strength steroid,
and only 57% displaying full skin-blanching
to the very potent steroid (x2=21.1, df=2,
p<0.001).
Cytokines and cortisol
The mean¡S.E.M. TNF-a level in the depress-
ives was 22.02¡3.62 pg/ml and in the controls
was 12.10¡2.56 pg/ml (t=2.255, df=36, p=
0.03). The mean¡S.E.M. IL-6 level in the
depressed was 1.18¡0.12 pg/ml and in the con-
trols was 0.73¡0.11 pg/ml (t=2.712, df=36,
p=0.01) (see Fig. 3). There was no statistically
signiﬁcant diﬀerence between the serum cor-
tisol concentrations of the depressives (325.5¡
26.4 nmol/l) and the controls (294.6¡28.3
nmol/l) (t=1.47, df=33, p=0.15).
Correlations
Relationships between SIV ratings in response
to the moderately potent topical steroid (the
lowest dose steroid which best discriminated the
groups), HAMD scores and cytokine levels
were explored using Spearman rank correlations.
There was a signiﬁcant inverse correlation be-
tween TNF-a concentrations and SIV scores
in the depressives (r=x0.46, p=0.04), as well
as a signiﬁcant negative correlation between
HAMD and SIV scores (r=x0.66, p=0.0018).
No relationship was established between serum
cortisol and either IL-6, TNF-a or SIV scores.
DISCUSSION
The main ﬁndings in this study are that de-
pressed subjects who fail to respond to an
antidepressant show a reduced vasoconstrictor
response to topical application of steroids when
compared to healthy matched controls, while
also having signiﬁcantly higher circulating
pro-inﬂammatory cytokines. Our ﬁnding of a
decreased vasoconstrictor response is in keeping
with the results of Cotter et al. (2002) but not
those of Coupland et al. (2003). The contrast
with the latter may be due to the fact that in
their study only female patients were recruited,
were drug free and less severely ill than in our
study.
We established a relationship between TNF-a
levels and vasoconstrictor response whereby the
higher the concentration of circulating TNF-a,
the lower the score on the vasoconstriction
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FIG. 2. Full skin-blanching response to topical steroid application
in severe depression (. . . ... . . .), mild/moderate depression (- -m- -)
and healthy controls (—&—).
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FIG. 1. Percentage of depressed subjects (- -&- -) and controls
(—&—) displaying a full skin-blanching response to topical steroid
application.
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assay (implying the less sensitive the cutaneous
GR). The negative correlation found between
HAMD scores and vasoconstrictor response
implies that there is an inverse relationship
between the severity of the depressive episode
and the sensitivity of peripheral GRs.
As previous studies have demonstrated that
the reduction in peripheral GR sensitivity in
depression may not be the result of hypercorti-
solaemia (Cotter et al. 2002), the ﬁnding of
an association between pro-inﬂammatory cyto-
kines and GR sub-sensitivity in this study
suggests a possible causal mechanism for altered
peripheral GR sensitivity in major depressives.
We were unable to establish a relationship be-
tween cortisol and GR response, which supports
the conclusion of Cotter et al. (2002) that
cortisol is not directly responsible for the sub-
sensitivity. However, a limitation of our study
is the fact that only one sample was taken
for cortisol estimation which provides a crude
measure of cortisol production. No measure of
cortisol level following the application of the
steroid cream is available. Furthermore, we did
not complete a dexamethasone suppression test,
which would have yielded interesting data on
the response of a separate population of GRs.
The molecular mechanisms through which
cytokines can inﬂuence the GR have been
explored in previous studies (Miller et al. 1999;
Pariante et al. 1999). These found that cytokines
can exert their eﬀects on GR function by one
of two ways. First, through binding to speciﬁc
membrane receptors and activation of second-
ary messenger cascades, they inhibit GR-
mediated gene transcription, and furthermore,
they inhibit GR translocation from cytoplasm
to nucleus via possible interactions with heat-
shock proteins, one of the constituents of the
cytoplasmic GR complex. Wang et al. (2004)
demonstrated that pro-inﬂammatory cytokine
inhibition of GR function is associated with
activation of the p38 mitogen-activated protein
kinase signal transduction pathway. This may
explain the current ﬁndings.
The skin-blanching assay is a well established
method for ranking the eﬃcacy of cortico-
steroids, with the degree of vasoconstriction
correlating well with the clinical eﬃcacy of the
steroid (Barry & Woodford, 1978). It has been
shown to be sensitive, precise and reproducible
(Place et al. 1970; Barry & Woodford, 1978).
The inference from our study is that the eﬃcacy
of topical steroids in patients with inﬂammatory
skin disorders and co-morbid depression is
markedly reduced, with impairment in eﬃcacy
being correlated with the severity of depression.
This would be of importance in conditions such
as eczema and psoriasis, which are known to
have signiﬁcant co-morbidity with depression
(Jowett & Ryan, 1985) and for which topical
steroids are often the ﬁrst-line treatment.
It has previously been shown that depressed
mood can impact negatively on the course of
inﬂammatory bowel disorder (IBD) (Mitter-
maier et al. 2004). Patients with IBD and
co-morbid depression have been found to re-
quire higher doses of steroids than those with
IBD alone (Szigethy et al. 2004). Depressive
symptoms in asthmatics predict worse asthma
outcomes (Mancusso et al. 2001) and, interest-
ingly, limited data suggest that administration
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FIG. 3. (a) TNF-a and (b) IL-6 levels in patients with major depression (&) compared to healthy controls (m).
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of antidepressants to asthmatics can improve
asthmatic symptoms as well as depression
(Zielinski et al. 2000).
The ﬁndings of our study suggest the link
between depression and inﬂammatory disorders
may be found in the expression of pro-
inﬂammatory cytokines which can produce
symptoms of depression, render the GR recep-
tor sub-sensitive and thereby potentially result
in inﬂammatory disorders requiring higher
doses of steroids for eﬀective treatment.
However, it is inappropriate to suggest that
a sub-sensitive cutaneous GR necessarily means
that peripheral GRs in general are also sub-
sensitive as there is data suggesting that
glucocorticoid sensitivity in depressed patients
remains intact in some tissues or compartments.
Speciﬁcally, depressed patients have been found
to exhibit increased intra-abdominal fat depo-
sition (Thakore et al. 1997) and decreased bone
mineral density (Michelson et al. 1996) sugges-
ting that GRs in these tissues may maintain their
sensitivity to glucocorticoids, although this view
is rejected by Raison & Miller (2003) who argue
that such changes are due to insuﬃcient gluco-
corticoid signalling. Future studies should
examine GR function in diﬀerent tissues in the
same patients whilst provided a more in-depth
analysis of cortisol production.
Chronic antidepressant use in animal studies
has been reported to up-regulate GRs (Seckl &
Fink, 1992), a ﬁnding which could not explain
our results of reduced sensitivity to topical
steroids. However, such up-regulation may not
occur in antidepressant-resistant depression. It
is also of note that in previous clinical studies,
no diﬀerence in lymphocyte GRs has been
shown between medicated and non-medicated
depressed patients (Yehuda et al. 1991). It is
possible however, that SIV may be inﬂuenced
by eﬀects of antidepressants on vascular tone
downstream to GRs. For example, glucocorti-
coids potentiate noradrenaline-induced vaso-
constriction (Walker & Williams, 1992), and
noradrenergic function may be increased by
antidepressants (Checkley et al. 1986). Repli-
cation of this study in drug-free depressives
would be of interest in controlling for this eﬀect.
In conclusion, this study suggest that cu-
taneous GR function is abnormal in anti-
depressant-resistant depression, that circulating
TNF-a may play a signiﬁcant role in this
abnormality and that the eﬃcacy of topical
steroids in antidepressant-resistant depressives
is reduced.
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